Boys Arnold & Co’s Edwards Lifesciences EW Stock Holding History

Boys Arnold & Co’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4,266	Closed	-$207K	–	279
2018 Q2	$207K	Buy	+4,266	New	+$199K	0.03%	267

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Boys Arnold & Co's EW Position: Q3 2018 in Review

Boys Arnold & Co sold out of Edwards Lifesciences (EW) in Q3 2018, closing a stake of 4,266 shares — an estimated $207K sold.

Boys Arnold & Co first reported a position in EW in Q2 2018 and held it in 1 quarter. The position peaked at $207K in Q2 2018. 852 funds tracked by Wall St. Rank hold EW as of Q3 2018.

Boys Arnold & Co reported no remaining Edwards Lifesciences position as of Q3 2018 after selling out during the quarter.
Boys Arnold & Co sold 4,266 Edwards Lifesciences shares in Q3 2018, an estimated $207K.
Boys Arnold & Co first reported a position in Edwards Lifesciences in Q2 2018 and held it in 1 quarter.
Boys Arnold & Co's Edwards Lifesciences position peaked at $207K in Q2 2018.
852 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2018.

Based on Boys Arnold & Co's 13F filing for Q3 2018, filed 31 Oct 2018.